Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
HONG KONG, GERMANTOWN, MD & SUZHOU BIOBAY, CHINA, July 23, 2024 – (ACN Newswire) – Sirnaomics Ltd. (HKG: 2257), ‘Sirnaomics’ or the “Company”, together with subsidiaries the “Group”, a leading biopharmaceutical company engaging in the discovery and development of advanced RNAi therapeutics, announced today that it has completed IND-enabling studies for STP125G…
HONG KONG, GERMANTOWN, MD & SUZHOU BIOBAY, CHINA, July 23, 2024 – (ACN Newswire) – Sirnaomics Ltd. (HKG: 2257), ‘Sirnaomics’ or the “Company”, together with subsidiaries the “Group”, a leading biopharmaceutical company engaging in the discovery and development of advanced RNAi therapeutics, announced today that it has completed IND-enabling studies for STP125G…
Read More
About Author
